Table 1.
Fold changes of the reporter gene activities in ARPE-19 cells in response to oxLDL alone or combined with E3330.
Transcription factor | Reporter gene activity fold change | Pathway | |||||
---|---|---|---|---|---|---|---|
oxLDL/Control | p Value | oxLDL+E3330/oxLDL | p Value | oxLDL+E3330/Control | p Value | ||
Nrf2/Nrf1 | 1.71 | 0.008 | 0.60 | 0.003 | 0.84 | 0.409 | Antioxidant response |
p53 | 1.70 | 0.001 | 0.59 | 0.000 | 0.82 | 0.130 | DNA damage |
NFκB | 1.76 | 0.008 | 0.58 | 0.011 | 1.04 | 0.850 | NFκB |
HIF-1 | 1.65 | 0.012 | 0.63 | 0.021 | 1.08 | 0.658 | Hypoxia |
CBF/NF-Y/YY1 | 2.33 | 0.002 | 0.44 | 0.004 | 1.16 | 0.549 | ER stress |
MTF1 | 1.26 | 0.043 | 0.80 | 0.042 | 1.00 | 0.980 | Heavy metal stress |
HSF-1 | 1.59 | 0.000 | 0.63 | 0.002 | 1.22 | 0.024 | Heat shock |
Glucocorticoid Receptor (GR) | 1.49 | 0.015 | 0.68 | 0.312 | 1.33 | 0.065 | Glucocorticoid |
AP-1 | 1.43 | 0.039 | 0.71 | 0.113 | 1.13 | 0.465 | MAPK/JNK |
AhR | 1.65 | 0.004 | 0.61 | 0.094 | 1.36 | 0.047 | Xenobiotic |
OxLDL versus Con, 150 μg/mL oxLDL challenge versus vehicle control.
OxLDL+E3330 versus oxLDL, concomitant treatment of 150 μg/mL oxLDL plus 30 μM E3330 versus 150 μg/mL oxLDL challenge.
OxLDL+E3330 versus Con, concomitant treatment of 150 μg/mL oxLDL plus 30 μM E3330 versus vehicle control.